B cell Therapy to Treat an Axonal Neuropathyin Mixed Connective Tissue Disease
محل انتشار: علوم اعصاب کاسپین، دوره: 3، شماره: 8
سال انتشار: 1396
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 254
فایل این مقاله در 8 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_CJNS-3-8_006
تاریخ نمایه سازی: 18 اسفند 1397
چکیده مقاله:
The B cell is a vital contributor to humoral immunity. The B cell-specific antigen CD20 is expressed during B cell development, starting at the pre-B cell level and persists through B cell differentiation, but is lost during terminal differentiation to plasma cells. Rituximab is a monoclonal antibody that destroys both normal and malignant B cells that have CD20 on their surfaces and is therefore used to treat diseases characterized by excessive B cells, overactive B cells, or dysfunctional B cells. The connective tissue diseases and vasculitis mediated by B cell may cause various disorders of the peripheral nervous system especially axonal neuropathy. B cell–directed therapies may represent a promising new treatment for autoimmune axonal neuropathies.
کلیدواژه ها:
نویسندگان
David Lyman
MD, MPH retired, Department of Family Medicine, University of Tennessee, Jackson, Tennessee